This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTGN Neon Therapeutics (NTGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Neon Therapeutics Stock (NASDAQ:NTGN) 30 days 90 days 365 days Advanced Chart Get Neon Therapeutics alerts:Sign Up Key Stats Today's Range$3.07▼$3.0750-Day Range$2.77▼$3.0752-Week Range$0.88▼$6.25VolumeN/AAverage Volume516,108 shsMarket Capitalization$88.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More… Receive NTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NTGN Stock News HeadlinesBCYC Bicycle Therapeutics plcApril 9, 2024 | seekingalpha.comNTGN_old Historical DataFebruary 20, 2024 | investing.com[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.April 25, 2025 | Colonial Metals (Ad)NBCO Neon Bloom, Inc.December 22, 2023 | seekingalpha.comMacbeth review – neon-tinted remix plays like a cinematic thrillerMarch 1, 2023 | theguardian.comSee More Headlines NTGN Stock Analysis - Frequently Asked Questions How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) announced its earnings results on Monday, March, 2nd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03. When did Neon Therapeutics IPO? Neon Therapeutics (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager. What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neon Therapeutics investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), Aduro Biotech (ADRO) and Altimmune (ALT). Company Calendar Last Earnings3/02/2020Today4/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NTGN CIKN/A Webwww.neontherapeutics.com Phone617-337-4701FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-199.09% Return on Assets-137.14% Debt Debt-to-Equity Ratio0.43 Current Ratio1.58 Quick Ratio3.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.14Miscellaneous Outstanding Shares28,967,000Free FloatN/AMarket Cap$88.93 million OptionableNot Optionable Beta-0.81 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:NTGN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Neon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.